HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

R-102444

structure in first source

Also Known As:

(2R,4R)-4-lauryloxy-2-(2-(2-(2-(3-methoxyphenyl)ethyl)phenoxyl)-ethyl)1-methylpyrrolidine hydrochloride

Networked: 3 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyrrolidines: 115
    - R-102444: 3

Experts

1.	Asai, Fumitoshi: 2 articles (10/2005 - 02/2004)
2.	Fujimoto, Koichi: 2 articles (10/2005 - 02/2004)
3.	Ogawa, Taketoshi: 2 articles (10/2005 - 02/2004)
4.	Sugidachi, Atsuhiro: 2 articles (10/2005 - 02/2004)
5.	Tanaka, Naoki: 2 articles (10/2005 - 02/2004)
6.	Fukushige, Jun-ichiro: 1 article (10/2005)
7.	Tani, Yoshiro: 1 article (10/2005)
8.	Asai, F: 1 article (11/2000)
9.	Fujimoto, K: 1 article (11/2000)
10.	Goto, R: 1 article (11/2000)

Related Diseases

1.	Chronic Pancreatitis 10/03/2005 - "The effect of R-102444 was further examined in male Wistar Bonn/Kobori rats (4-9 months of age) which spontaneously show pancreatic fibrosis and parenchymal destruction compatible with human chronic pancreatitis. " 10/03/2005 - "These results clearly indicate that R-102444 and R-96544 inhibit the progression of acute and chronic pancreatitis and support the contention of possible involvement of 5-HT2A receptors in the progression of experimental pancreatitis." 10/03/2005 - "The effects of R-102444 ((2R, 4R)-4-lauroyloxy-2-[2-[2-[2-(3-methoxy)phenyl]ethyl]phenoxy]ethyl-1-methylpyrrolidine hydrochloride) and its active metabolite R-96544 ((2R, 4R)-2-[2-[2-[2-(3-methoxy)phenyl]ethyl]phenoxy]ethyl-4-hydroxy-1-methylpyrrolidine hydrochloride), potent and selective 5-hydroxytryptamine 2A (5-HT2A) receptor antagonists, on development of pancreatitis were investigated in experimental models of acute and chronic pancreatitis. " 10/03/2005 - "Effects of R-102444 and its active metabolite R-96544, selective 5-HT2A receptor antagonists, on experimental acute and chronic pancreatitis: Additional evidence for possible involvement of 5-HT2A receptors in the development of experimental pancreatitis."
2.	Peripheral Vascular Diseases (Peripheral Vascular Disease) 02/01/2004 - "Based on these results, we conclude that 5-HT2A receptor activation is involved in peripheral vascular disease in the rat and that R-102444 is a useful oral agent for the investigation of diseases involving 5-HT2A receptor activation." 02/01/2004 - "Effects of R-102444, an orally active 5-HT2A receptor antagonist, in rat models of peripheral vascular disease." 02/01/2004 - "The effects of R-102444 on peripheral vascular disease were examined using two different rat models: one induced by lauric acid and the other by ergotamine plus epinephrine. "
3.	Thrombosis (Thrombus) 11/01/2000 - "In addition, R-102444 exhibited more potent antithrombotic effects than sarpogrelate in a rat photochemically-induced thrombosis model."
4.	Pancreatitis 10/03/2005 - "These results clearly indicate that R-102444 and R-96544 inhibit the progression of acute and chronic pancreatitis and support the contention of possible involvement of 5-HT2A receptors in the progression of experimental pancreatitis." 10/03/2005 - "In Wistar Bonn/Kobori rats (from 3 to 9 months of age) fed a diet containing 0.017% and 0.17% of R-102444, pancreatic weight, pancreatic protein and amylase content were higher compared to those in non-treated pancreatitis control rats. " 10/03/2005 - "The effects of R-102444 ((2R, 4R)-4-lauroyloxy-2-[2-[2-[2-(3-methoxy)phenyl]ethyl]phenoxy]ethyl-1-methylpyrrolidine hydrochloride) and its active metabolite R-96544 ((2R, 4R)-2-[2-[2-[2-(3-methoxy)phenyl]ethyl]phenoxy]ethyl-4-hydroxy-1-methylpyrrolidine hydrochloride), potent and selective 5-hydroxytryptamine 2A (5-HT2A) receptor antagonists, on development of pancreatitis were investigated in experimental models of acute and chronic pancreatitis. " 10/03/2005 - "Effects of R-102444 and its active metabolite R-96544, selective 5-HT2A receptor antagonists, on experimental acute and chronic pancreatitis: Additional evidence for possible involvement of 5-HT2A receptors in the development of experimental pancreatitis."
5.	Gangrene 02/01/2004 - "Both 5-day treatments with R-102444 (1-30 mg/kg/day p.o., o.d.), one commenced 1 h before the injection of epinephrine plus ergotamine and one just after injection, resulted in the prevention of rat tail gangrene in a dose-dependent manner, whereas sarpogrelate (100 mg/kg) produced a minimal protection in this model. "

Related Drugs and Biologics

1.	5-HT2A Serotonin Receptor (5 HT2A Receptor)
2.	sarpogrelate
3.	Serotonin (5 Hydroxytryptamine)
4.	Proteins (Proteins, Gene)
5.	Ergotamine (Ergotamine Tartrate)
6.	Epinephrine (Adrenaline)
7.	Amylases
8.	(2R,4R)- 4- hydroxy- 2- (2- (2- (2- (3- methoxy)phenyl)ethyl)phenoxy)ethyl- 1- methylpyrrolidine hydrochloride
9.	lauric acid (dodecanoic acid)